{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Poly+I%3A+Poly+C12U+%28Rintatolimod%29&page=2",
    "query": {
      "intervention": "Poly I: Poly C12U (Rintatolimod)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Poly+I%3A+Poly+C12U+%28Rintatolimod%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Poly+I%3A+Poly+C12U+%28Rintatolimod%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T06:53:55.769Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01312389",
      "title": "A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "OC-L/Montanide ISA 51 VG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ampligen",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 3,
      "start_date": "2011-04",
      "completion_date": "2012-08-17",
      "has_results": true,
      "last_update_posted_date": "2021-11-15",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01312389"
    },
    {
      "nct_id": "NCT03899987",
      "title": "Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Adenocarcinoma",
        "Stage I Prostate Cancer AJCC v8",
        "Stage II Prostate Cancer AJCC v8",
        "Stage IIA Prostate Cancer AJCC v8",
        "Stage IIB Prostate Cancer AJCC v8",
        "Stage IIC Prostate Cancer AJCC v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage IIIA Prostate Cancer AJCC v8",
        "Stage IIIB Prostate Cancer AJCC v8",
        "Stage IIIC Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "EC Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Recombinant Interferon Alfa-2b",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 12,
      "start_date": "2019-11-29",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-09",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03899987"
    },
    {
      "nct_id": "NCT03734692",
      "title": "Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer Recurrent"
      ],
      "interventions": [
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Robert Edwards",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2019-01-28",
      "completion_date": "2027-01-10",
      "has_results": true,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03734692"
    },
    {
      "nct_id": "NCT05756166",
      "title": "Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Unresectable Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Interferon Alpha-2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rintatolimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2024-02-16",
      "completion_date": "2025-06-19",
      "has_results": true,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05756166"
    },
    {
      "nct_id": "NCT00001000",
      "title": "A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Ampligen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 20,
      "start_date": null,
      "completion_date": "1990-01",
      "has_results": false,
      "last_update_posted_date": "2012-10-19",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001000"
    },
    {
      "nct_id": "NCT01545141",
      "title": "Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Colorectal Carcinoma",
        "Colorectal Tumors",
        "Neoplasms, Colorectal"
      ],
      "interventions": [
        {
          "name": "Chemokin Modulatory Regimen (5 MU/m2)",
          "type": "DRUG"
        },
        {
          "name": "Chemokin Modulatory Regimen (10 MU/m2)",
          "type": "DRUG"
        },
        {
          "name": "Chemokin Modulatory Regimen (20 MU/m2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2012-10",
      "completion_date": "2017-04-08",
      "has_results": true,
      "last_update_posted_date": "2023-10-27",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01545141"
    },
    {
      "nct_id": "NCT01591473",
      "title": "Safety Study of FluMist With and Without Ampligen",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human"
      ],
      "interventions": [
        {
          "name": "Poly I:Poly C12U 50 ug",
          "type": "DRUG"
        },
        {
          "name": "Poly I:Poly C12U 200 ug",
          "type": "DRUG"
        },
        {
          "name": "Poly I:Poly C12U 500 ug",
          "type": "DRUG"
        },
        {
          "name": "Poly I:Poly C12U 1250 ug",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "FluMist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AIM ImmunoTech Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "19 Years to 49 Years"
      },
      "enrollment_count": 55,
      "start_date": "2012-04",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2018-07-26",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01591473"
    },
    {
      "nct_id": "NCT00035581",
      "title": "Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Seropositivity",
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "poly I-poly C12U",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AIM ImmunoTech Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2001-05",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2013-04-17",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 7,
      "location_summary": "Fountain Valley, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 4 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00035581"
    },
    {
      "nct_id": "NCT02432378",
      "title": "Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer of Ovary",
        "Cancer of the Ovary",
        "Neoplasms, Ovarian",
        "Ovarian Cancer",
        "Ovary Cancer",
        "Ovary Neoplasms"
      ],
      "interventions": [
        {
          "name": "Cisplatin + celecoxib + DC vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin + CKM + Celecoxib + DC Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2015-09-04",
      "completion_date": "2025-06-19",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02432378"
    },
    {
      "nct_id": "NCT00215813",
      "title": "Ampligen in Chronic Fatigue Syndrome",
      "overall_status": "TEMPORARILY_NOT_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Chronic Fatigue Syndrome"
      ],
      "interventions": [
        {
          "name": "Poly I: Poly C12U (Rintatolimod)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AIM ImmunoTech Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-10T06:53:55.769Z",
      "location_count": 2,
      "location_summary": "Incline Village, Nevada • Charlotte, North Carolina",
      "locations": [
        {
          "city": "Incline Village",
          "state": "Nevada"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00215813"
    }
  ]
}